Dupilumab effectively treats eosinophilic esophagitis in real-world practice, reducing white blood cell counts in the food pipe by 86% and achieving symptom improvement in 86% of patients on weekly dosing and 81% on bi-weekly dosing, with no significant difference between the two schedules according to a 2026 analysis of 161 European patients in the EoE CONNECT registry.
A large European study of 161 patients found that dupilumab, a newer medication, effectively treats eosinophilic esophagitis (EoE)—a condition where too many white blood cells build up in the food pipe, causing swallowing problems and pain. According to Gram Research analysis, the drug worked equally well whether patients received it once a week or every two weeks, with about 86% of patients experiencing significant improvement in symptoms and cell counts after six months. The medication was also safe and well-tolerated, with only 5% of patients stopping treatment due to side effects.
Key Statistics
A 2026 cross-sectional analysis of 161 patients from the EoE CONNECT registry found that dupilumab reduced peak eosinophil counts from 57 cells to 8 cells per high-power field after a median of 6.5 months of treatment.
In the 2026 EoE CONNECT registry study of 161 patients, 86% of those receiving weekly dupilumab dosing and 81% receiving bi-weekly dosing achieved clinico-histological response, with no statistically significant difference between the two schedules (p=0.57).
According to the 2026 EoE CONNECT registry analysis of 161 patients, dose escalation from bi-weekly to weekly dupilumab rescued improvement in 80% of non-responders, while dose reduction was successful in all 8 evaluable cases.
The 2026 EoE CONNECT registry study of 161 eosinophilic esophagitis patients found that only 5% discontinued dupilumab treatment, primarily due to adverse events, indicating strong tolerability in real-world clinical practice.
The Quick Take
- What they studied: How well dupilumab works for treating eosinophilic esophagitis in real-world patients, and whether different dosing schedules (once weekly versus every two weeks) make a difference in effectiveness.
- Who participated: 161 patients from European hospitals, including 145 adults and 16 teenagers, all diagnosed with eosinophilic esophagitis. About 69% had fibrotic features like rings or strictures in their food pipes.
- Key finding: After about 6.5 months of treatment, white blood cell counts in the food pipe dropped dramatically from 57 cells to 8 cells per high-power field (p<0.001), and 86% of patients on weekly dosing and 81% on bi-weekly dosing achieved significant clinical improvement with no meaningful difference between the two schedules.
- What it means for you: If you have eosinophilic esophagitis, dupilumab appears to be an effective treatment option that can be flexibly dosed based on your needs. However, this is real-world data from Europe; talk with your doctor about whether this medication is appropriate for your specific situation.
The Research Details
This study analyzed data from the EoE CONNECT registry, Europe’s largest collection of eosinophilic esophagitis patient information. Researchers looked at 161 patients who were already receiving dupilumab treatment in regular clinical practice (not a controlled experiment). They collected information about how patients started the medication, what dose they received (300 mg once weekly or every two weeks), how their symptoms changed, and what side effects they experienced. The study measured success by looking at three things: how many white blood cells were in the food pipe (using a microscope), how the food pipe looked during endoscopy (a camera test), and how much patients’ symptoms improved.
This type of study is called ‘real-world evidence’ because it shows what actually happens when doctors use a medication in everyday practice, rather than in a controlled research setting. Researchers followed patients for a median of 6.5 months and tracked whether they needed to change their dose up or down based on how well the treatment worked.
Real-world studies are important because they show whether medications work outside of controlled research environments. The previous information about dupilumab came mostly from clinical trials with strict rules about who could participate. This study shows that the drug works well for a broader range of patients in actual medical practice, including those with more severe disease features like strictures (narrowing of the food pipe). It also provides practical information about flexible dosing, which helps doctors decide how to treat individual patients.
This study has several strengths: it’s from a large, well-established European registry with prospective data collection (meaning doctors recorded information as they treated patients, not looking back at old records). The sample size of 161 patients is reasonable for this type of analysis. However, the study is observational rather than randomized, meaning patients weren’t randomly assigned to different doses—doctors chose the dose based on clinical judgment. This makes it harder to prove that one dose is definitively better than another. The study also lacks a control group of untreated patients, so we can’t compare dupilumab to doing nothing or to other treatments. Additionally, the study is from Europe, so results may not apply equally to other populations.
What the Results Show
The study showed dramatic improvements in all three main measures of disease severity. White blood cell counts in the food pipe (peak eosinophil count) dropped from an average of 57 cells to 8 cells per high-power field—a reduction of about 86%. The EREFS score, which measures how damaged the food pipe looks during endoscopy, improved from 3.0 to 1.3 on a scale where higher numbers mean more damage. Symptom severity scores improved from 5.8 to 2.5, meaning patients reported much less difficulty swallowing and pain.
When researchers looked at whether patients achieved ‘clinico-histological response’ (meaning both their symptoms and cell counts improved significantly), 86% of patients on weekly dosing and 81% on bi-weekly dosing met this goal. Importantly, there was no statistically significant difference between the two dosing schedules (p=0.57), suggesting that doctors can choose the dosing frequency based on patient preference and other factors rather than effectiveness alone.
The study also examined what happened when doctors adjusted doses. Eight patients had their dose reduced from weekly to less frequent dosing (semi-weekly or monthly), and all eight maintained their improvement. Four of five patients who weren’t responding well had their dose increased from bi-weekly to weekly, and four of these five (80%) then showed improvement.
The research identified which patients were most likely to receive bi-weekly dosing instead of weekly dosing. Patients with severe atopy (a tendency toward allergic reactions) were 26.9 times more likely to receive bi-weekly dosing, suggesting doctors may adjust doses based on allergic disease severity. Patients with conjunctivitis (eye inflammation), asthma, or multiple food allergies were also more likely to receive the less frequent dosing schedule. Only 8 patients (5%) stopped taking dupilumab, and most of these discontinuations were due to adverse events, indicating the medication was generally well-tolerated. The medication appeared to work well even in the 69% of patients who had fibrotic features like rings or strictures in their food pipes—a group that’s sometimes harder to treat.
This real-world data aligns with and extends previous clinical trial results showing dupilumab’s effectiveness for eosinophilic esophagitis. Earlier controlled studies demonstrated that dupilumab reduced eosinophil counts and improved symptoms, but those studies typically used fixed dosing schedules. This registry study provides new information about flexible dosing in everyday practice, showing that doctors can successfully adjust doses based on patient response without losing effectiveness. The high response rate (86%) is consistent with or slightly better than what was seen in clinical trials, suggesting the medication performs well outside of research settings. The low discontinuation rate (5%) is also reassuring compared to some other EoE treatments.
This study has several important limitations. First, it’s observational, meaning doctors chose which patients got which doses based on clinical judgment rather than random assignment, so we can’t be completely certain that both doses are equally effective—the groups may have differed in ways that affected outcomes. Second, there’s no control group of untreated patients or patients on other medications, so we can’t compare dupilumab to alternative treatments. Third, the follow-up period was relatively short (median 6.5 months), so we don’t know about long-term effectiveness or safety beyond this timeframe. Fourth, the study population is from Europe, so results may not apply equally to other geographic regions or populations. Finally, the study didn’t report on quality of life measures or patient satisfaction, which are important outcomes for people living with this condition.
The Bottom Line
For patients with eosinophilic esophagitis, dupilumab appears to be an effective treatment option that can be dosed flexibly (weekly or bi-weekly) based on individual needs and response. The evidence is strong (based on real-world data from 161 patients) that the medication significantly reduces white blood cell counts and improves symptoms in most patients. Doctors may consider starting with either weekly or bi-weekly dosing and adjusting based on response. However, this should only be done under medical supervision, as dupilumab is a prescription medication that requires proper monitoring.
This research is most relevant for adults and adolescents with diagnosed eosinophilic esophagitis who are considering or currently using dupilumab. It’s also important for gastroenterologists and allergists who treat EoE patients. People with eosinophilic esophagitis who have tried other treatments without success may find this information particularly helpful. However, this study doesn’t apply to people without EoE or those with other esophageal conditions. Individual treatment decisions should always be made in consultation with a healthcare provider.
Based on this study, most patients showed significant improvement within 6.5 months of starting dupilumab. However, individual responses vary. Some patients may see benefits sooner, while others may need the full 6+ months to achieve maximum improvement. If a patient isn’t responding well after a few months, doctors may consider increasing the dose, which rescued 80% of non-responders in this study. Long-term benefits beyond 6.5 months are not yet clear from this research.
Frequently Asked Questions
Is dupilumab effective for eosinophilic esophagitis?
Research shows dupilumab is highly effective for eosinophilic esophagitis in real-world practice. A 2026 study of 161 patients found it reduced white blood cell counts by 86% and achieved symptom improvement in 86% of patients within 6.5 months, with only 5% discontinuing due to side effects.
How often do you need to take dupilumab for eosinophilic esophagitis?
Dupilumab can be given either weekly or every two weeks for eosinophilic esophagitis. A 2026 registry study of 161 patients found both schedules equally effective (86% vs. 81% improvement rates), so your doctor can choose based on your preference and response to treatment.
What happens if dupilumab doesn’t work for eosinophilic esophagitis?
If dupilumab isn’t working, your doctor may increase the dose frequency from bi-weekly to weekly. A 2026 study found this dose escalation rescued improvement in 80% of non-responders, suggesting it’s worth trying before switching to a different medication.
Can you reduce dupilumab dose if it’s working well?
Yes, dose reduction appears possible if dupilumab is working well. A 2026 study of 161 patients found that all 8 patients who had their dose reduced from weekly to less frequent dosing maintained their improvement, though this should only be done under medical supervision.
How long does it take for dupilumab to work for eosinophilic esophagitis?
Most patients show significant improvement within 6.5 months of starting dupilumab, according to a 2026 study of 161 patients. However, individual responses vary, and your doctor may adjust your dose if you’re not improving after a few months.
Want to Apply This Research?
- Track weekly swallowing difficulty on a 0-10 scale and food avoidance patterns. Note which foods trigger symptoms and any changes in ability to eat solid foods versus liquids. Record any medication side effects or changes in other allergic symptoms (asthma, eczema, allergies).
- Work with your doctor to establish a baseline symptom score before starting or adjusting dupilumab. Use the app to log daily swallowing ease, meals consumed, and any discomfort. This data helps your doctor determine if your current dose is working or if adjustment is needed. Share monthly summaries with your healthcare provider.
- Create monthly check-ins to review symptom trends and discuss with your doctor whether your current dose is optimal. If symptoms worsen or don’t improve after 2-3 months, flag this for your doctor to consider dose escalation. If you’re doing very well, track this too—your doctor may eventually consider dose reduction (as was successful in 8 patients in this study). Set reminders for endoscopy follow-ups as recommended by your doctor to objectively measure improvement.
This article summarizes research findings and is not medical advice. Eosinophilic esophagitis is a serious medical condition that requires professional diagnosis and treatment. Dupilumab is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Individual treatment decisions should be made in consultation with your doctor, who can assess your specific medical situation, consider alternative treatments, and monitor for side effects. This study represents real-world data from European patients and may not apply equally to all populations. Always consult your gastroenterologist or allergist before starting, stopping, or changing any medication.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.